Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 196

Sort by

Sort Order Select

Journal Articles

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Michele S. Redell, Todd A. Alonzo, Robert Gerbing, Jim Wang, Maureen M. O'Brien, Gwen Nichols, Laura Di Laurenzio, Sarah K. Tasian, C. Michel Zwaan, Dirk Reinhardt, E. Anders Kolb, Todd Cooper

Blood (2023) 142 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2023-190947

Published: 2023

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Nucleophosmin (NPM1) Type D Genotype Is Associated with Distinct Outcome in Acute Myeloid Leukemia - an AIEOP-BFM and COG-SWOG Intergroup Collaboration

Martina Pigazzi, Claudia Tregnago, Rhonda E Ries, Maddalena Benetton, Todd A. Alonzo, Nicolas Duployez, Edwin Sonneveld, Jonas Abrahamsson, Linda Fogelstrand, Nils Von Neuhoff, Henrik Hasle, Dirk Reinhardt, Franco Locatelli, Soheil Meshinchi

Blood (2023) 142 (Supplement 1): 840.

https://doi.org/10.1182/blood-2023-181872

Published: 2023

Journal Articles

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1533.

https://doi.org/10.1182/blood-2023-184745

Published: 2023

Journal Articles

Treatment of Molecular Relapses in Pediatric AML Saves Toxicities Prior to Hematopoietic Stem Cell Transplantation (HSCT) - Results of AMoRe2017 Trial

Amelie Polutta, Dirk Reinhardt, Andre Baruchel, Henrik Hasle, Franco Locatelli, C. Michel Zwaan, Michael Frühwald, Silke Westphal, Michael Dworzak, Heidrun Boztug, Gabriele Escherich, Thomas Lehrnbecher, Bianca F. Goemans, Brigitte Strahm, Markus Schneider, Lina Hoffmeister, Katharina Waack

Blood (2023) 142 (Supplement 1): 1521.

https://doi.org/10.1182/blood-2023-180820

Published: 2023

Journal Articles

Characteristics of FLT3 -ITD and Efficacy of Sorafenib Treatment in Pediatric AML: A Report from AML-BFM Study Group

Evangelia Antoniou, Annika Puschnig, Lina Marie Hoffmeister, Amani Awada, Nils Von Neuhoff, Markus Schneider, Dirk Reinhardt, Naghmeh Niktoreh

Blood (2023) 142 (Supplement 1): 4217.

https://doi.org/10.1182/blood-2023-187465

Published: 2023

Journal Articles

Europeanpediatric Acute Leukemia (EuPAL) Registry

Katarzyna Majstrowicz, Katharina Waack, Evangelia Antoniou, Naghmeh Niktoreh, Gwen Nichols, Laura Di Laurenzio, Michele S. Redell, Todd Cooper, E. Anders Kolb, Sarah K. Tasian, Franco Locatelli, C. Michel Zwaan, Dirk Reinhardt

Blood (2023) 142 (Supplement 1): 1496.

https://doi.org/10.1182/blood-2023-189684

Published: 2023

Journal Articles

RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia

Blood (2023) 141 (10): 1105–1118.

https://doi.org/10.1182/blood.2022017619

Published: 2023

Includes: Supplemental data

Journal Articles

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Blood (2022) 140 (Supplement 1): 551–554.

https://doi.org/10.1182/blood-2022-167480

Published: 2022

Journal Articles

Molecular Relapse in Pediatric AML: Clinical Relapse May be Predicted By Increasingin MRD Level - Experiences from Real-World Data in Patients with Inv(16), t(8;21), t(9;11), t(10;11) or NPM1

Katharina Waack, Katharina Andernacht, Christiane Walter, Markus Schneider, Nils Von Neuhoff, Sophia Hahn, Amani Awada, Dirk Reinhardt

Blood (2022) 140 (Supplement 1): 6326–6327.

https://doi.org/10.1182/blood-2022-169495

Published: 2022

Journal Articles

ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia

Sae Ishimaru, Gwenaëlle Gueguen, Seth E. Karol, Francisco J. Bautista Sirvent, Valeria Ceolin, Bianca F. Goemans, Marlous Bakker, Laura Di Laurenzio, Jennifer Lukin, Harm Van Tinteren, Gauri B. Sunkersett, Maika Onishi, Kristina Unnebrink, Dirk Reinhardt, Gwen L Nichols, E. Anders Kolb, C. Michel Zwaan

Blood (2022) 140 (Supplement 1): 3369–3370.

https://doi.org/10.1182/blood-2022-168818

Published: 2022

Journal Articles

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Blood (2022) 140 (Supplement 1): 6053–6055.

https://doi.org/10.1182/blood-2022-165088

Published: 2022

Journal Articles

Downregulation of the Mutated WT1 Alleles in Malignant Hematopoietic Cells Via Nonsense-Mediated mRNA Decay Contradicts Their Prognostic Impact

Lisa Weber, Christiane Walter, Markus Schneider, Hans Günther Drexler, Dirk Reinhardt, Helmut Hanenberg, Naghmeh Niktoreh

Blood (2022) 140 (Supplement 1): 11498–11499.

https://doi.org/10.1182/blood-2022-168591

Published: 2022

Journal Articles

RUNX1 Mutations Have Distinct Prognostic and Clinical Implication in Pediatric AML: Results of the AML-BFM Study Group

Stephanie Sendker, Markus Schneider, Amani Awada, Eser Orhan, Michael Sendker, Lina Hoffmeister, Evangelia Antoniou, Dirk Reinhardt, Nils Von Neuhoff

Blood (2022) 140 (Supplement 1): 9110–9112.

https://doi.org/10.1182/blood-2022-167465

Published: 2022

Journal Articles

Guiding Pups with Severe Hemophilia a and Their Parents from Diagnosis to a Full Prophylactic Schedule Mitigating the Risk of Bleed and the Risk for Inhibitor Formation - a Single Centre Approach

Susan Halimeh, Hannelore Rott, Manuela Siebert, Günther Kappert, Dirk Reinhardt

Blood (2022) 140 (Supplement 1): 8472–8473.

https://doi.org/10.1182/blood-2022-168988

Published: 2022

Journal Articles

Revision of Complete Remission Criteria in Pediatric AML

Evangelia Antoniou, Annika Puschnig, Katharina Waack, Carolin Augsburg, Christel Katerkamp, Denise Kondryn, Tabea Ziedrich, Nils von Neuhoff, Dirk Reinhardt, Stephanie Sendker

Blood (2022) 140 (Supplement 1): 1016–1017.

https://doi.org/10.1182/blood-2022-170648

Published: 2022

Journal Articles

RAS Pathway Alterations in Pediatric AML Patients

Kevin Hai-Ning Lu, Lina Hoffmeister, Eser Orhan, Markus Schneider, Katharina Waack, Helmut Hanenberg, Nils von Neuhoff, Dirk Reinhardt

Blood (2022) 140 (Supplement 1): 6110–6111.

https://doi.org/10.1182/blood-2022-170747

Published: 2022

Journal Articles

Management and Outcome of Hyperleukocytosis As Early Complication in Childhood AML - an AML-BFM Experience

Katharina Waack, Franziska Budeus, Evangelia Antoniou, Dirk Reinhardt

Blood (2022) 140 (Supplement 1): 6084–6085.

https://doi.org/10.1182/blood-2022-169455

Published: 2022

Journal Articles

Second Malignancy after Childhood AML Treatment - a Retrospective Analysis of the AML-BFM Stud

Katharina Waack, Daniel Weber, Stephanie Sendker, Dirk Reinhardt

Blood (2022) 140 (Supplement 1): 6082–6083.

https://doi.org/10.1182/blood-2022-168829

Published: 2022

Journal Articles

The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis

Oriol Alejo-Valle, Karoline Weigert, Raj Bhayadia, Michelle Ng, Hasan Issa, Christoph Beyer, Stephan Emmrich, Konstantin Schuschel, Christian Ihling, Andrea Sinz, Martin Zimmermann, Claudia Wickenhauser, Marius Flasinski, Eniko Regenyi, Maurice Labuhn, Dirk Reinhardt, Marie-Laure Yaspo, Dirk Heckl, Jan-Henning Klusmann

Blood (2022) 139 (5): 651–665.

https://doi.org/10.1182/blood.2021012231

Published: 2022

Includes: Supplemental data

NARROW

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Nucleophosmin (NPM1) Type D Genotype Is Associated with Distinct Outcome in Acute Myeloid Leukemia - an AIEOP-BFM and COG-SWOG Intergroup Collaboration

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Treatment of Molecular Relapses in Pediatric AML Saves Toxicities Prior to Hematopoietic Stem Cell Transplantation (HSCT) - Results of AMoRe2017 Trial

Characteristics of FLT3 -ITD and Efficacy of Sorafenib Treatment in Pediatric AML: A Report from AML-BFM Study Group

Europeanpediatric Acute Leukemia (EuPAL) Registry

RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Molecular Relapse in Pediatric AML: Clinical Relapse May be Predicted By Increasingin MRD Level - Experiences from Real-World Data in Patients with Inv(16), t(8;21), t(9;11), t(10;11) or NPM1

ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Downregulation of the Mutated WT1 Alleles in Malignant Hematopoietic Cells Via Nonsense-Mediated mRNA Decay Contradicts Their Prognostic Impact

RUNX1 Mutations Have Distinct Prognostic and Clinical Implication in Pediatric AML: Results of the AML-BFM Study Group

Guiding Pups with Severe Hemophilia a and Their Parents from Diagnosis to a Full Prophylactic Schedule Mitigating the Risk of Bleed and the Risk for Inhibitor Formation - a Single Centre Approach

Revision of Complete Remission Criteria in Pediatric AML

RAS Pathway Alterations in Pediatric AML Patients

Management and Outcome of Hyperleukocytosis As Early Complication in Childhood AML - an AML-BFM Experience

Second Malignancy after Childhood AML Treatment - a Retrospective Analysis of the AML-BFM Stud

The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only